Susan K. Parsons

Susan K. Parsons

Auto-generated profile, based on publicly available information

Susan K. Parsons

Division of Hematology and Oncology and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Psychological Assessment
Verified
Journal Article
Closed access
CRChristopher J. Recklitis
Christopher J. Recklitis
SPSusan K. Parsons
Susan K. Parsons
MSMei-Chiung Shih
Mei-Chiung Shih
AMAnn Mertens
Ann Mertens
LRLeslie L. Robison
Leslie L. Robison
LZLonnie Zeltzer
Lonnie Zeltzer
The factor structure of the Brief Symptom Inventory--18 (BSI-18; L. R. Derogatis, 2000) was investigated in a sample of adult survivors of childhood cancer enrolled in the Childhood Cancer Survivor Study (CCSS; N = 8,945). An exploratory factor analysis with a randomly chosen subsample supported a 3-factor structure closely corresponding to the 3 BSI-18 subscales: Depression, Anxiety, and Somatization. Confirmatory factor analysis with structural equation modeling validated this 3-dimensional structure in a separate subsample, though an alternative 4-factor model also fit the data. Analysis of the 3-factor model showed consistent fit in male and female participants. Compared with available community-based norms, survivors reported fewer symptoms of psychological distress. Together, results support the hypothesized 3-dimensional structure of the BSI-18 and indicate the measure may be useful in assessing psychological distress in this growing population of cancer survivors.

26 December 2011 in Medical Care Research and Review
Verified
Journal Article
Closed access
PDF file
BPBrian W. Pennarola
Brian W. Pennarola
ARAngie Mae Rodday
Angie Mae Rodday
DMDeborah K. Mayer
Deborah K. Mayer
SRSara J. Ratichek
Sara J. Ratichek
SDStella M. Davies
Stella M. Davies
FSfor the HSCT-CHESS Study*
for the HSCT-CHESS Study*
Patient activation, the extension of self-efficacy into self-management, is an essential component of effective chronic care. In pediatric populations, caregiver activation is also needed for proper disease management. This study investigates the relationships between parental activation and other characteristics of parent–child dyads (N = 198) presenting for pediatric hematopoietic stem cell transplant. Parental activation concerning their child’s health was assessed using the Parent Patient Activation Measure (Parent-PAM), a modified version of the well-validated Patient Activation Measure (PAM). Using hierarchical linear regression and following the Belsky process model for determining parenting behaviors, a multivariate model was created for parental activation on behalf of their child that showed that the parent’s age, rating of their own general health, self-activation, and duration of the child’s illness were significantly related to Parent-PAM score. Our findings characterize a potentially distinct form of activation in a parent–child cohort preparing for a demanding clinical course.

6 August 2011 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
SPSusan K. Parsons
Susan K. Parsons
DFDiane L. Fairclough
Diane L. Fairclough
JWJim Wang
Jim Wang
PHPamela S. Hinds
Pamela S. Hinds

10 April 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ARAngie Mae Rodday
Angie Mae Rodday
SPSusan K. Parsons
Susan K. Parsons
JUJenica N. Upshaw
Jenica N. Upshaw
JFJonathan W. Friedberg
Jonathan W. Friedberg
Andrea GallaminiAndrea Gallamini
Andrea Gallamini
AEAndrew M Evens
Andrew M Evens
PURPOSE: The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients. Harnessing multisource individual patient data from the Hodgkin Lymphoma International Study for Individual Care consortium, we developed and validated a modern clinical prediction model. METHODS: Model development via Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines was performed on 4,022 patients with newly diagnosed advanced-stage adult cHL from eight international phase III clinical trials, conducted from 1996 to 2014. External validation was performed on 1,431 contemporaneously treated patients from four real-world cHL registries. To consider association over a full range of continuous variables, we evaluated piecewise linear splines for potential nonlinear relationships. Five-year progression-free survival (PFS) and overall survival (OS) were estimated using Cox proportional hazard models. RESULTS: The median age in the development cohort was 33 (18-65) years; nodular sclerosis was the most common histology. Kaplan-Meier estimators were 0.77 for 5-year PFS and 0.92 for 5-year OS. Significant predictor variables included age, sex, stage, bulk, absolute lymphocyte count, hemoglobin, and albumin, with slight variation for PFS versus OS. Moreover, age and absolute lymphocyte count yielded nonlinear relationships with outcomes. Optimism-corrected c-statistics in the development model for 5-year PFS and OS were 0.590 and 0.720, respectively. There was good discrimination and calibration in external validation and consistent performance in internal-external validation. Compared with the IPS, there was superior discrimination for OS and enhanced calibration for PFS and OS. CONCLUSION: We rigorously developed and externally validated a clinical prediction model in > 5,000 patients with advanced-stage cHL. Furthermore, we identified several novel nonlinear relationships and improved the prediction of patient outcomes. An online calculator was created for individualized point-of-care use.

30 April 2007 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
CCCatherine Chen
Catherine Chen
SJStefanie Jeruss
Stefanie Jeruss
JCJocelyn S. Chapman
Jocelyn S. Chapman
NTNorma Terrin
Norma Terrin
HTHocine Tighiouart
Hocine Tighiouart
SPSusan K. Parsons
Susan K. Parsons

29 July 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
NLNadine Linendoll
Nadine Linendoll
TSTully Saunders
Tully Saunders
RBRebecca Burns
Rebecca Burns
JNJonathan D. Nyce
Jonathan D. Nyce
KWKristen B. Wendell
Kristen B. Wendell
SPSusan K. Parsons
Susan K. Parsons
Hodgkin Lymphoma (HL) is highly curable with well-established treatment regimens; however, the impact on patient’s health-related quality of life (HRQL) from diagnosis through survivorship is unclear. This systematic review aimed to describe the available literature on HRQL in HL, assess the quality of these studies, identify gaps in the literature and recommend further areas of research. Following PRISMA guidelines, we performed a systematic review to include studies assessing the HRQL in HL patients. Articles identified through database searches were screened and data extracted. Quality was evaluated using a 6-point scale, adapted from published HRQL systematic reviews. Sixty five articles published between 1986 and 2015 met inclusion criteria. These included 53 (82 %) cross-sectional studies; 12 (18 %) longitudinal studies, including three embedded in randomized trials; and three additional longitudinal studies that began assessment at diagnosis. Study sample sizes of HL patients varied considerably with only five (42 %) longitudinal studies including more than 50 patients. Multidimensional HRQL was assessed in 45 studies, single HRQL domains in 22 studies, and symptoms, including fatigue, in 28 studies. The majority of studies employed a cross-sectional design, enrolling HL survivors at least 10 years after the completion of therapy. Emphasis on HRQL following therapy may inform initial treatment decisions and long-term survivorship goals. We recommend that future research include prospective, longitudinal randomized designs across both treatment and time.